These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses. Kitchin JE; Pomeranz MK; Pak G; Washenik K; Shupack JL J Am Acad Dermatol; 1997 Sep; 37(3 Pt 1):445-9. PubMed ID: 9308561 [TBL] [Abstract][Full Text] [Related]
5. [Mycophenolate mofetil: a new immunosuppressive drug in dermatology and its possible uses]. Geilen CC; Orfanos-Boeckel H; Offermann G; Orfanos CE Hautarzt; 2000 Feb; 51(2):63-9. PubMed ID: 10743574 [TBL] [Abstract][Full Text] [Related]
9. Long-term safety of mycophenolate mofetil and cyclosporine: a review. Buell C; Koo J J Drugs Dermatol; 2008 Aug; 7(8):741-8. PubMed ID: 18720690 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic evaluation of mycophenolate mofetil for pemphigus. Doukaki S; Pistone G; Aricò M; Bongiorno MR Expert Opin Drug Metab Toxicol; 2011 Feb; 7(2):237-44. PubMed ID: 21192770 [TBL] [Abstract][Full Text] [Related]
11. [Mycophenolate mofetil in the treatment of selected connective tissue diseases]. Batko B; Krawiec P; Osieleniec J; Sułowicz W Przegl Lek; 2013; 70(9):724-9. PubMed ID: 24455833 [TBL] [Abstract][Full Text] [Related]
12. Red blood cell anemia in a patient with pemphigus vulgaris induced by the use of mycophenolate mofetil and prednisone. Scheinfeld N J Dermatolog Treat; 2007; 18(4):243-5. PubMed ID: 17671884 [TBL] [Abstract][Full Text] [Related]
13. An evaluation of the usefulness of mycophenolate mofetil in pemphigus. Powell AM; Albert S; Al Fares S; Harman KE; Setterfield J; Bhogal B; Black MM Br J Dermatol; 2003 Jul; 149(1):138-45. PubMed ID: 12890207 [TBL] [Abstract][Full Text] [Related]
14. Mycophenolate mofetil and skin diseases. Hartmann M; Enk A Lupus; 2005; 14 Suppl 1():s58-63. PubMed ID: 15803935 [TBL] [Abstract][Full Text] [Related]
15. Mycophenolate mofetil may serve as a steroid-sparing agent for sarcoidosis. Kouba DJ; Mimouni D; Rencic A; Nousari HC Br J Dermatol; 2003 Jan; 148(1):147-8. PubMed ID: 12534610 [TBL] [Abstract][Full Text] [Related]
16. An analysis of the dermatological uses of mycophenolate mofetil in a tertiary hospital. George L; Hamann I; Chen K; Choi J; Fernandez-Peñas P J Dermatolog Treat; 2015 Feb; 26(1):63-6. PubMed ID: 24286467 [TBL] [Abstract][Full Text] [Related]
17. Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil. Grundmann-Kollmann M; Mooser G; Schraeder P; Zollner T; Kaskel P; Ochsendorf F; Boehncke WH; Kerscher M; Kaufmann R; Peter RU J Am Acad Dermatol; 2000 May; 42(5 Pt 1):835-7. PubMed ID: 10775866 [TBL] [Abstract][Full Text] [Related]
18. Mycophenolate mofetil as a first-line steroid-sparing agent in the treatment of pemphigus vulgaris. Vyas N; Patel NS; Cohen GF J Drugs Dermatol; 2013 Feb; 12(2):210-6. PubMed ID: 23377396 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of long-term mycophenolate sodium therapy in pemphigus vulgaris. Baskan EB; Yilmaz M; Tunali S; Saricaoglu H J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1432-4. PubMed ID: 19470052 [TBL] [Abstract][Full Text] [Related]
20. Mycophenolate mofetil as a systemic antipsoriatic agent: positive experience in 11 patients. Geilen CC; Arnold M; Orfanos CE Br J Dermatol; 2001 Mar; 144(3):583-6. PubMed ID: 11260019 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]